الفهرس 
Introduction
Intracytoplasmic Sperm Injection (ICSI)Only 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
Our study was conducted from 2013 to 2014. Three hundred infertile patients treated by ICSI and given Gn-RH agonist long downregulation protocol and meeting the inclusion criteria were included. These patients were recruited from Global Nile Infertility Center. These patients were randomly allocated to three groups. In the first group, patients received a single dose of Gn-RH agonist, 0.1 ml Leuprolide SC (Lucrin 0.1 ml; Abbott, France) 6 days after ICSI (3 days after embryo transfer). In the second group, patients received three daily doses of Gn-RH agonist, 0.1 ml Leuprolide SC (Lucrin 0.1 ml; Abbott, France) starting from day 6 after ICSI ( oocyte retrieval ). Patients in the third group ( control group ) received placebo at the same time after ICSI. Progesterone support was given for all patients as natural micronized progesterone (Cyclogest; Actavis, UK) vaginally in doses of 400 mg twice a day starting from the day of oocyte retrieval and continued for 6 weeks if patients got pregnant. Approval for the study was obtained from the Hospital Ethics Committee .
Inclusion criteria :
1. Couples undergoing ICSI with their own gametes .
2. Couples having at least two good embryo available for transfer .
3. All downregulated cycles .
Exclusion criteria :
1. Age more than 38 years old .
2. Intramural fibroid more than 4 cm or adenomyosis .
3. Endometrium less than 6 mm on the day of hCG .
4. Cryopreserved embryos .
Clinical pregnancy, implantation and ongoing pregnancy rates were chosen as the main outcome measures .
There were 54 % clinical pregnancies in the first group (single dose Gn-RH agonist group), 39 % in the second group (three doses Gn-RH agonist group) and 32 % in the control group. There were 30.33 % , 22.67 % and 21.33 implantation rates in the three groups respectively. Ongoing pregnancy rates were 45 % , 30 % and 28 % in the three groups respectively.
On the basis of the results of this study we conclude that luteal phase Gn-RH agonist administration resulted in an increase in the implantation, clinical pregnancy per transfer and ongoing pregnancy rates when compared with the controls. On the other hand, our results demonstrated statistically significant higher clinical pregnancy, implantation and ongoing pregnancy rates in cycles that received a single dose than that received three doses of Gn-RH agonist administration.